"Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination
- PMID: 21075163
- PMCID: PMC3175433
- DOI: 10.1016/j.vaccine.2010.10.076
"Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination
Abstract
The Step Study phase IIb HIV-1 vaccine trial was terminated early due to futility; subsequent analyses revealed increased susceptibility to HIV infection among a subset of test vaccine recipients. We conducted a mixed methods investigation, including a brief, self-administered baseline questionnaire and in-depth, semi-structured, 1-h interviews after unblinding, to explore experiences and perspectives among trial participants and key informants. Interviews were digitally recorded, transcribed, and analyzed using NVivo and thematic techniques. Forty-eight trial participants (46 gay/bisexual men) completed baseline surveys; 15 (14 gay/bisexual men) engaged in post-trial interviews. Participants indicated surprise and disappointment about the early trial termination and unexpected risks. Some articulated understanding the uncertainties of clinical trials, steadfast support and willingness to participate in the future; others reported greater risks than they deemed acceptable and unlikelihood of volunteering again. A few indicated mistrust of trial sponsors and ethics. Participants' most profound criticism was not about unexpected results, but perceived delays in unblinding and gaps in post-trial dissemination of information. Future HIV vaccine trials may benefit from increased emphasis on: (1) communication mechanisms among participants, investigators and trial sponsors, and (2) post-trial dissemination of information and psychosocial support.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):521-8. doi: 10.1097/00126334-200212150-00010. J Acquir Immune Defic Syndr. 2002. PMID: 12473841
-
Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men.Vaccine. 2010 Jun 23;28(29):4638-43. doi: 10.1016/j.vaccine.2010.04.073. Epub 2010 May 7. Vaccine. 2010. PMID: 20452428
-
Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials.AIDS Care. 2012;24(10):1249-54. doi: 10.1080/09540121.2012.656566. Epub 2012 Feb 24. AIDS Care. 2012. PMID: 22360605
-
An update on human immunodeficiency virus vaccine preparedness studies.J Med Microbiol. 2015 Jul;64(7):731-738. doi: 10.1099/jmm.0.000073. Epub 2015 Apr 23. J Med Microbiol. 2015. PMID: 25908608 Review.
-
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.Curr Opin HIV AIDS. 2010 Sep;5(5):357-61. doi: 10.1097/COH.0b013e32833d2d2b. Curr Opin HIV AIDS. 2010. PMID: 20978374 Free PMC article. Review.
Cited by
-
Innovations in HIV-1 Vaccine Design.Clin Ther. 2020 Mar;42(3):499-514. doi: 10.1016/j.clinthera.2020.01.009. Epub 2020 Feb 5. Clin Ther. 2020. PMID: 32035643 Free PMC article. Review.
-
Bridging the divide: HIV prevention research and Black men who have sex with men.Am J Public Health. 2014 Apr;104(4):708-14. doi: 10.2105/AJPH.2013.301653. Epub 2014 Feb 13. Am J Public Health. 2014. PMID: 24524520 Free PMC article.
-
Perceived enablers and barriers of community engagement for vaccination in India: Using socioecological analysis.PLoS One. 2021 Jun 25;16(6):e0253318. doi: 10.1371/journal.pone.0253318. eCollection 2021. PLoS One. 2021. PMID: 34170920 Free PMC article.
-
Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding.AIDS Res Hum Retroviruses. 2014 Nov;30(11):1041-5. doi: 10.1089/AID.2013.0136. Epub 2014 Jul 8. AIDS Res Hum Retroviruses. 2014. PMID: 24906244 Free PMC article. Clinical Trial.
-
"Why Don't You Go Into Suburbs? Why Are You Targeting Us?": Trust and Mistrust in HIV Vaccine Trials in South Africa.J Empir Res Hum Res Ethics. 2018 Dec;13(5):525-536. doi: 10.1177/1556264618804740. J Empir Res Hum Res Ethics. 2018. PMID: 30417754 Free PMC article.
References
-
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand. N Engl J Med. 2009;23(361):2209–2220. - PubMed
-
- Michael N. RV 144 Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thai Adults; 17th Conference on Retroviruses and Opportunistic Infections (CROI): Abstract 74. Presented February 18, 2010; http://retroconference.org/2010/Abstracts/39837.htm.
-
- Dolin R. HIV vaccine trial results--an opening for further research. N Engl J Med. 2009;361(23):2279–2280. - PubMed
-
- Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or ‘high-risk’ pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26(8):1091–1097. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical